...
首页> 外文期刊>Theranostics >HDAC6-specific inhibitor suppresses Th17 cell function via the HIF-1α pathway in acute lung allograft rejection in mice
【24h】

HDAC6-specific inhibitor suppresses Th17 cell function via the HIF-1α pathway in acute lung allograft rejection in mice

机译:HDAC6特异性抑制剂通过小鼠急性肺同种异体移植物排斥反应的HIF-1α途径抑制TH17细胞功能

获取原文
           

摘要

Background: Previous animal experiments and clinical studies indicated the critical role of Th17 cells in lung transplant rejection. Therefore, the downregulation of Th17 cell function in lung transplant recipients is of great interest. Methods: We established an orthotopic mouse lung transplantation model to investigate the role of histone deacetylase 6-specific inhibitor (HDAC6i), Tubastatin A, in the suppression of Th17 cells and attenuation of pathologic lesions in lung allografts. Moreover, mechanism studies were conducted in vitro. Results: Tubastatin A downregulated Th17 cell function in acute lung allograft rejection, prolonged the survival of lung allografts, and attenuated acute rejection by suppressing Th17 cell accumulation. Consistently, exogenous IL-17A supplementation eliminated the protective effect of Tubastatin A. Also, hypoxia-inducible factor-1α (HIF-1α) was overexpressed in a lung transplantation mouse model. HIF-1α deficiency suppressed Th17 cell function and attenuated lung allograft rejection by downregulating retinoic acid-related orphan receptor γt (ROR γt) expression. We showed that HDAC6i downregulated HIF-1α transcriptional activity under Th17-skewing conditions in vitro and promoted HIF-1α protein degradation in lung allografts. HDAC6i did not affect the suppression of HIF-1α -/- na?ve CD4 T cell differentiation into Th17 cell and attenuation of acute lung allograft rejection in HIF-1α-deficient recipient mice. Conclusion: These findings suggest that Tubastatin A downregulates Th17 cell function and suppresses acute lung allograft rejection, at least partially, via the HIF-1α/ RORγt pathway.? The author(s).
机译:背景:先前的动物实验和临床研究表明Th17细胞在肺移植排斥中的关键作用。因此,肺移植受者在肺移植受者中的下调是非常兴趣的。方法:我们建立了一种原位小鼠肺移植模型,探讨组蛋白脱乙酰酶6特异性抑制剂(HDAC6i),Tabastatin A,抑制Th17细胞的作用以及肺同种异体移植物中病理病变的衰减。此外,体外进行机制研究。结果:Tuchastatin在急性肺同种异体移植排斥反应中的下调Th17细胞功能,延长了肺同种异体移植物的存活,并通过抑制Th17细胞积累来减毒急性排斥反应。始终如一地,外源性IL-17A补充消除了Cupastatin A的保护作用。此外,缺氧诱导因子-1α(HIF-1α)在肺移植小鼠模型中过表达。 HIF-1α缺乏抑制TH17细胞功能并通过下调视黄酸相关的孤儿受体γt(RORγT)表达来抑制肺同种异体移植物排斥反应。我们展示HDAC6i在体外,在肺同种异体移植物中促进HIF-1α蛋白质降解的TH17-偏移条件下的HIF-1α转录活性。 HDAC6I不影响HIF-1α - / - -NA'VE CD4 T细胞分化为Th17细胞和HIF-1α缺陷的受体小鼠中急性肺同种异体移植抑制的衰减。结论:这些发现表明,通过HIF-1α/RORγT途径,Cupastatin a下调Th17细胞功能并至少部分地抑制急性肺同种异体移植排斥反应。作者。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号